According to a new market research study titled “Organoids Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Type, Application, and Source,” the global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. The report highlights the trends prevalent in the global organoids market and the factors driving the market along with those that act as deterrents to its growth. The market is expected to grow due to increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing models.

Animal models are widely used in biomedical research for human-specific diseases. However, various cases demonstrate that animal models cannot always be predictive for human drug response, for instance, drug toxicology studies. This is because there are wide variations in the metabolism of drugs and toxins in humans compared to animals, which makes it nearly impossible to study drug metabolism in experimental models, such as laboratory rodent species. Additionally, in recent years, several regulations have been implemented that restrict animal use in research activities. Similarly, several bodies, such as Cruelty-Free International and the Fund for the Replacement of Animals in Medical Experiments, oppose animal-based models for research purposes.

Therefore, in order to develop alternative testing models that can provide an environment with full equivalence to the human body, various institutes are involved in developing alternative methods for drug development and biomedical research. As organoids can serve as alternatives to animal models, the current focus on reducing animal use in research is expected to support the growth of the human organoids market.

Download Sample Report @ https://www.theinsightpartners.com/sample/TIPRE00017616/

Based on type, the global organoids market is segmented into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. In 2019, the intestine segment held the largest market share. This segment is also expected to dominate the market in 2027 as various experimental techniques have also been developed in parallel with, and applied to, intestinal organoid cultures with a scientifically synergistic effect. Moreover, the kidney segment is anticipated to grow at the fastest rate during the forecast period.

The emergence of coronavirus pandemic is estimated to have a significant impact on the organoids market. Majority of the pharmaceutical companies around the globe are engaged in the development of vaccine for coronavirus. Moreover, COVID-19 has also caused increased interest in human lung organoid models.  However, this shift of focus is anticipated to have a positive impact on the other segments of the market. Disruptions in supply chain caused due to halt in global operations are projected to have an adverse impact on the market.

Prominent players operating in organoids market include STEMCELL Technologies, Inc.; Cellesce Ltd.; Hubrecht Organoid Technology; Definigen, 3Dnamics, Inc.; Organoid Therapeutics; PeproTech, Inc.; Thermo Fisher Scientific; Corning Incorporated (Life Sciences); and Merck KGgA.

The market players are focused toward bringing new and innovative products and services to sustain their position in the market. For instance, in January 2020 Merck and BioMed X0020collaborated a for new research program in autoimmune diseases. This research would involve use of conventional and high-throughput metagenomics and generation of intestinal organoids from murine and human subjects for identification of biomarkers of autoimmune diseases. Such developments are expected to boost the market growth during the forecast period.

The report segments the global organoids market as follows:

Global Organoids Market – by Type

1.    Stomach

2.    Intestine

3.    Liver

4.    Pancreas

5.    Lung

6.    Brain

7.    Kidney

8.    Others

Global Organoids Market – by Application

1.    Developmental Biology

2.    Disease Pathology of Infectious Disease

3.    Regenerative Medicine

4.    Drug Toxicity and Efficacy Testing

5.    Drug Discovery and Personalized Medicine

6.    Others

Global Organoids Market – by Source

1.    Pluripotent Stem Cells

2.    Organ-Specific Adult Stem Cells

Merck KGaA and Thermo Fisher Scientific Inc. - Notable Market Participants in Transient Protein Expression Industry

The transient protein expression market is highly competitive in nature with considerable number of players, having a high level of consolidation overall revenue share. Most of the companies operating in the transient protein expression market are present globally and have wide distribution and sales network through partnerships or authorized dealers.

The most notable market participants are Thermo Fisher Scientific, Promega Corporation, Merck Kgaa, Takara Bio Inc, Qiagen, Genscript, Meridian Bioscience, Inc, Agilent Technologies, Inc., New England Biolabs, And Mirus Bio Llc., Sino Biological Inc. occupying a considerable share of the market owing to their offerings to the market.

Market leaders are involved in extensive research for the development of new transient protein expression and therapeutics with better efficiency and treatment outcomes. For instance, in Jan 2020, Ambrx and Sino Biopharma Announced Collaboration to Develop Two Next-Generation Biologics to develop two products enabled by Ambrx's unique non-natural amino acid incorporation technology platforms. The collaboration combines Ambrx's clinically validated ReCODE and EuCODE platforms with Sino Biopharma's strong resources and commitment to bring next-generation biologic drugs to market.

Many well-known as well as small local companies are present in the market to provide diversified products to its customers. The larger firms are adopting the strategy of acquiring small firms to enhance its product portfolio and expand its footprint in different geographies. Additionally various companies are also undergoing other strategic alliances such as collaborations and others to garner their significance and remain competitive in the market.

Few on the important key developments from the industry are mentioned below:

2020    Merck signed agreements licensing its CRISPR technology to two companies PanCELLa, a cell therapy firm, and Takara Bio USA, Inc., a biotechnology company. Licenses aim to accelerate drug discovery research leading to the development of new therapies, PanCELLa agreement marks Merck’s first CRISPR license for bioproduction, Takara Bio USA agreement gives access to Merck’s CRISPR integration and vector technologies for Takara’s vector products and cell engineering services.         

2018    QIAGEN announced the appointment of The Scientific Group, a South Africa-based company and a wholly-owned subsidiary of Ascendis Medical, as its exclusive commercial partner for Africa, excluding South Africa and the Maghreb. The agreement will raise the profile of QIAGEN’s Sample to Insight solutions in Africa and benefit a region with growing needs for modern molecular testing technologies in healthcare and the life sciences.        

2017    Thermo Fisher Scientific Inc. launched its new PureLink Fast Low-Endotoxin Plasmid Purification Midi and Maxi Kits which significantly reduces plasmid purification time to accelerate protein expression         North America

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1–646–491–9876